Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.74 ^USD	-11.22%		-19.07%	-3.06%

Mar. 15	North American Morning Briefing : Inflation -2-	DJ
Mar. 14	Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Brooklyn ImmunoTherapeutics, Inc. Announces the resignation of Kevin D’Amour as Chief Scientific Officer

July 27, 2022 at 04:30 pm EDT

On July 21, 2022, Dr. Kevin D'Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc. delivered his notice of resignation. The Company and Dr. D'Amour have not yet determined the effective date of Dr. D'Amour's resignation.

Latest news about Eterna Therapeutics Inc.

North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Eterna Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala, JD to Its Board of Directors	Feb. 20	CI
Eterna Therapeutics Inc. Announces Appointment of Peter Cicala to the Board of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee	Feb. 16	CI
Eterna Therapeutics Inc. Announces Management Changes	Jan. 19	CI
Eterna Therapeutics Inc Announces Chief Executive Officer Changes, Effective January 1, 2024	Dec. 20	CI
Eterna Therapeutics Inc Appoints Sanjeev Luther as President and Member of the Board of Directors, Effective January 1, 2024	Dec. 20	CI
Eterna Therapeutics Inc. Appoints James Bristol as Chairman of the Board	Dec. 20	CI
Eterna Therapeutics Selling $9.2 Million of Convertible Promissory Notes, Accompanying Warrants	Dec. 15	MT
Eterna Therapeutics Inc. announced that it expects to receive $9.2 million in funding	Dec. 13	CI
Eterna Therapeutics Inc. announced that it has received $1.5 million in funding	Dec. 07	CI
Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited	Nov. 16	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Eterna Therapeutics Inc. Appoints James Bristol to Its Board of Directors	Nov. 01	CI
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer	23-10-30	MT
Gregory Fiore Resigns from Eterna Therapeutics Inc.'s Board of Directors	23-10-05	CI
Lineage Cell Therapeutics, Inc. Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics	23-09-06	CI
Eterna Therapeutics Inc. Appoints Ms. Dorothy J. Clarke as Director, Effective on August 28, 2023	23-08-31	CI
Eterna Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Eterna Therapeutics Inc. Announces Management Changes	23-08-10	CI
Eterna Therapeutics Inc. announced that it has received $8.715 million in funding	23-07-12	CI
Eterna Therapeutics Inc. Announces Board Changes	23-07-11	CI
Eterna Therapeutics Inc.(NasdaqCM:ERNA) dropped from Russell 3000E Index	23-06-23	CI
Eterna Therapeutics Inc.(NasdaqCM:ERNA) dropped from Russell Microcap Value Index	23-06-23	CI
Eterna Therapeutics Inc.(NasdaqCM:ERNA) dropped from Russell Microcap Index	23-06-23	CI

Chart Eterna Therapeutics Inc.

Duration

Period

More charts

Company Profile

Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
ETERNA THERAPEUTICS INC.	-3.06%	10.6M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research

Eterna Therapeutics Inc.

Equities

ERNA

US1140822099

Biotechnology & Medical Research

Brooklyn ImmunoTherapeutics, Inc. Announces the resignation of Kevin D’Amour as Chief Scientific Officer

Latest news about Eterna Therapeutics Inc.

Chart Eterna Therapeutics Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research